20 / 21
Page 54
Euro Pharma Chemistry & Future Pharma 2019
Research & Reviews: Journal ofPharmaceutical Analysis | ISSN : 2320-0812
June 27-28, 2019 | Amsterdam, Netherlands
12th World congress on
Joint Event
4
th
Pharmaceutical Chemistry Conference Future Pharma
Volume 08
Synthesis and carbonic anhydrase activity of some new sulfonamides
Serkan Levent, Begum Nurpelin Saglık, Betul Kaya Cavusoglu, Derya Osmaniye, Ulviye Acar Cevik, Deniz
Nezir, Oya Buyukemir, Yusuf Ozkay, Sukru Beydemir
and
Zafer Asım Kaplancikli
Anadolu University, Turkey
C
arbonic anhydrase (CAs) isozymes (EC 4.2.1.1) are being in almost all tissues of living organisms and
they catalyse CO
2
hydration to bicarbonate (HCO3-) and protons. Inhibition of these enzymes is clinically
in use for various classes of diuretics and systemically acting antiglaucoma agents for a long time. Nowadays,
researchers show that they have also effect on acting anticonvulsants, anti-obesity, anti-pain, and antitumor
agents/diagnostic tools. These isozymes CA diverge in their catalytic activity, subcellular localization and
susceptibility to different classes of inhibitors. Some of them are cytosolic (CA I, CA II, CA III, CAVII and
CA XIII), others are membrane bound (CA IV, CA IX, CA XII and CA XIV), two are mitochondrial (CA
VA and CA VB), and one is buried in saliva (CA VI). Sulfonamides are well known carbonic anhydrase
inhibitors (CAI) and a lot of studies were carried on to improve novel CAI. In this study, twelve 2-oxo-2-
((4-sulfamoylphenyl) amino) ethyl 4-substitutedpiperazine-1-carbodithioate were synthesized. The chemical
structures of the compounds were elucidated by IR, 1H NMR, 13C NMR and HRMS spectral data. The
carbonic anhydrase enzyme inhibitor activity was confirmed by used
in vitro
methods. The results indicated
that compound 3d showed good inhibition against hCAI enzyme.
Pharmaceutical Analysis 2019, Volume 08